Multifocal Motor Neuropathy: Current Therapies and Novel Strategies
Authors:
- Eduardo Nobile-OrazioENEduardo Nobile-Orazio
- Francesca GalliaFGFrancesca Gallia
- 21 March 2013
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 73 (5) , 397-406
Abstract
Multifocal motor neuropathy (MMN) is a purely motor mononeuritis multiplex characterized by the presence of conduction block on motor but not on sensory nerves and by the presence of high titers of anti-GM1 antibodies. Several data point to a pathogenetic role of the immune system in this neuropathy, although this has not yet been proved. Several uncontrolled studies and randomized controlled trials have demonstrated the efficacy of therapy with high-dose intravenous immunoglobulin (IVIg) in MMN. However, this therapy has a short-lasting effect that needs to be maintained with periodic infusions. This can be partly overcome by the use of subcutaneous immunoglobulin (SCIg) at the same dose. The high cost and need for repeated infusions have led to the search for other immune therapies, the efficacy of which have not yet been confirmed in randomized trials. In addition, some therapies, including corticosteroids and plasma exchange, are not only ineffective but have been associated with clinical worsening. More recently, a number of novel therapies have been investigated in MMN, including interferon-β1a, the anti-CD20 monoclonal antibody rituximab and the complement inhibitor eculizumab. Preliminary data from open-label uncontrolled studies show that some patients improve after these therapies; however, randomized controlled trials are needed to confirm efficacy. Until then, IVIg (and SCIg) remains the mainstay of treatment in MMN, and the use of other immune therapies should only be considered for patients not responding to, or becoming resistant to, IVIg.Keywords
This publication has 97 references indexed in Scilit:
- Subcutaneous Recombinant Interferon-β-1a (Rebif®)Drugs, 2011
- An open‐label trial of rituximab (Rituxan®) in multifocal motor neuropathyJournal of the Peripheral Nervous System, 2010
- RituximabDrugs, 2010
- Recent developments in low molecular weight complement inhibitorsMolecular Immunology, 2009
- Beneficial effect of rituximab monotherapy in multifocal motor neuropathyNeuromuscular Disorders, 2009
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectBlood, 2009
- Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patientsJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Rituximab treatment in patients with IVIg‐dependent immune polyneuropathy: A prospective pilot trialMuscle & Nerve, 2006
- Axon loss is an important determinant of weakness in multifocal motor neuropathyJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Treatment of IgM antibody associated polyneuropathies using rituximabJournal of Neurology, Neurosurgery & Psychiatry, 2003